FR09C0004I1 - - Google Patents

Info

Publication number
FR09C0004I1
FR09C0004I1 FR09C0004C FR09C0004I1 FR 09C0004 I1 FR09C0004 I1 FR 09C0004I1 FR 09C0004 C FR09C0004 C FR 09C0004C FR 09C0004 I1 FR09C0004 I1 FR 09C0004I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26805159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0004(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR09C0004I1 publication Critical patent/FR09C0004I1/fr
Application granted granted Critical
Publication of FR09C0004I2 publication Critical patent/FR09C0004I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR09C0004C 1998-11-10 2009-01-22 Pyrimidines comme inhibiteurs de reproduction du VIH Active FR09C0004I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10779298P 1998-11-10 1998-11-10
US14396299P 1999-07-15 1999-07-15
PCT/EP1999/007417 WO2000027825A1 (en) 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines

Publications (2)

Publication Number Publication Date
FR09C0004I1 true FR09C0004I1 (enrdf_load_stackoverflow) 2009-02-27
FR09C0004I2 FR09C0004I2 (fr) 2010-06-11

Family

ID=26805159

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0004C Active FR09C0004I2 (fr) 1998-11-10 2009-01-22 Pyrimidines comme inhibiteurs de reproduction du VIH

Country Status (41)

Country Link
US (5) US6878717B2 (enrdf_load_stackoverflow)
EP (2) EP1002795B1 (enrdf_load_stackoverflow)
JP (1) JP3635238B2 (enrdf_load_stackoverflow)
KR (1) KR100658489B1 (enrdf_load_stackoverflow)
CN (1) CN1214013C (enrdf_load_stackoverflow)
AP (1) AP1683A (enrdf_load_stackoverflow)
AR (1) AR024227A1 (enrdf_load_stackoverflow)
AT (2) ATE455107T1 (enrdf_load_stackoverflow)
AU (2) AU762523C (enrdf_load_stackoverflow)
BG (1) BG65103B1 (enrdf_load_stackoverflow)
BR (1) BRPI9915552B8 (enrdf_load_stackoverflow)
CA (1) CA2350801C (enrdf_load_stackoverflow)
CY (1) CY2008021I1 (enrdf_load_stackoverflow)
CZ (1) CZ301367B6 (enrdf_load_stackoverflow)
DE (3) DE69905683T2 (enrdf_load_stackoverflow)
DK (1) DK1002795T3 (enrdf_load_stackoverflow)
EA (1) EA004049B1 (enrdf_load_stackoverflow)
EE (1) EE05086B1 (enrdf_load_stackoverflow)
ES (2) ES2338760T3 (enrdf_load_stackoverflow)
FR (1) FR09C0004I2 (enrdf_load_stackoverflow)
HK (1) HK1048817B (enrdf_load_stackoverflow)
HR (2) HRP20080359B1 (enrdf_load_stackoverflow)
HU (2) HU227453B1 (enrdf_load_stackoverflow)
ID (1) ID28376A (enrdf_load_stackoverflow)
IL (2) IL143023A0 (enrdf_load_stackoverflow)
LT (1) LTC1002795I2 (enrdf_load_stackoverflow)
LU (1) LU91528I2 (enrdf_load_stackoverflow)
MY (1) MY121108A (enrdf_load_stackoverflow)
NL (1) NL300373I2 (enrdf_load_stackoverflow)
NO (3) NO318801B1 (enrdf_load_stackoverflow)
NZ (1) NZ511116A (enrdf_load_stackoverflow)
OA (1) OA11674A (enrdf_load_stackoverflow)
PL (1) PL204427B1 (enrdf_load_stackoverflow)
PT (1) PT1002795E (enrdf_load_stackoverflow)
SI (1) SI1002795T1 (enrdf_load_stackoverflow)
SK (2) SK287269B6 (enrdf_load_stackoverflow)
TR (1) TR200101306T2 (enrdf_load_stackoverflow)
TW (1) TWI238161B (enrdf_load_stackoverflow)
UA (1) UA70966C2 (enrdf_load_stackoverflow)
WO (1) WO2000027825A1 (enrdf_load_stackoverflow)
ZA (1) ZA200103769B (enrdf_load_stackoverflow)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05086B1 (et) * 1998-11-10 2008-10-15 Janssen Pharmaceutica N.V. Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
ES2258018T3 (es) 1999-09-24 2006-08-16 Janssen Pharmaceutica N.V. Dispersiones solidas antivirales.
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
CA2386218A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
CA2406562C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
CA2407754C (en) * 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines
US7418471B2 (en) * 2000-11-01 2008-08-26 Snapnames.Com, Inc. Domain name acquisition and management system and method
RU2330024C2 (ru) 2001-05-29 2008-07-27 Шеринг Акциенгезельшафт Ингибирующие cdk-киназы пиримидины, способ их получения и их применение в качестве лекарственных средств
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
UY27487A1 (es) 2001-10-17 2003-05-30 Boehringer Ingelheim Pharma Derivados de pirimidina, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparación
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
US7183288B2 (en) 2001-11-01 2007-02-27 Herwig Josephus Margareta Janssen, legal representative Amide derivatives as glycogen synthase kinase 3-β inhibitors
CA2463822A1 (en) 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1485099B1 (en) 2002-03-13 2010-07-07 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
DE60321324D1 (de) 2002-03-13 2008-07-10 Janssen Pharmaceutica Nv Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US20060034797A1 (en) * 2002-05-03 2006-02-16 Arien Albertina M E Polymeric micromulsions
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
TW200409629A (en) 2002-06-27 2004-06-16 Bristol Myers Squibb Co 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
JP2006514989A (ja) 2002-07-29 2006-05-18 ライジェル ファーマシューティカルズ ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
KR101086678B1 (ko) 2002-08-09 2011-11-25 얀센 파마슈티카 엔.브이. 4-[[4-[[4-(2-시아노에테닐)-2,6-디메틸페닐]아미노]-2-피리미디닐]아미노]벤조니트릴의 제조방법
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
MXPA05005547A (es) * 2002-11-28 2005-07-26 Schering Ag Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos.
BRPI0406761A (pt) 2003-01-14 2005-12-20 Arena Pharm Inc Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
ES2311146T3 (es) * 2003-02-07 2009-02-01 Janssen Pharmaceutica Nv 1,2,4-triazinas que inhiben el vih.
EP1597237B1 (en) 2003-02-07 2016-07-27 Janssen Pharmaceutica NV Pyrimidine derivatives for the prevention of HIV infection
CL2004000306A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
JP4634367B2 (ja) 2003-02-20 2011-02-16 スミスクライン ビーチャム コーポレーション ピリミジン化合物
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN1822843B (zh) * 2003-07-17 2010-04-28 泰博特克药品有限公司 制备含有抗病毒药物颗粒的方法
NZ545270A (en) 2003-07-30 2010-04-30 Rigel Pharmaceuticals Inc 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
ATE500254T1 (de) 2003-09-25 2011-03-15 Janssen Pharmaceutica Nv Die replikation von hiv hemmende purinderivate
US8099262B2 (en) 2004-03-02 2012-01-17 Virco Bvba Estimation of clinical cut-offs
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
AP2336A (en) 2004-07-28 2011-12-08 Janssen Pharmaceutica Nv Subsituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase.
AU2005271161B2 (en) 2004-08-10 2011-05-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
ATE520672T1 (de) 2004-09-30 2011-09-15 Tibotec Pharm Ltd Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
EP1797069B1 (en) 2004-09-30 2011-08-17 Tibotec Pharmaceuticals Hiv inhibiting 5-heterocyclyl pyrimidines
RU2410379C2 (ru) 2004-09-30 2011-01-27 Тиботек Фармасьютикалз Лтд. 5-замещенные пиримидины, ингибирующие вич
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
JP2008519073A (ja) * 2004-11-08 2008-06-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びエトラビリンの同時投与によるｈｉｖ感染症の治療法
SI1814878T1 (sl) 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
KR101278397B1 (ko) 2005-01-19 2013-06-25 리겔 파마슈티칼스, 인크. 2,4-피리미딘디아민 화합물의 전구약물 및 이의 용도
EP1853568B1 (en) 2005-01-27 2011-09-07 Tibotec Pharmaceuticals Hiv inhibiting 2-(4-cyanophenylamino)pyrimidine derivatives
SI1853588T1 (sl) 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
EP1853567B1 (en) 2005-02-18 2014-12-31 Janssen R&D Ireland Hiv inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
DK1858861T3 (da) * 2005-03-04 2010-11-08 Tibotec Pharm Ltd HIV-inhiberende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidiner
US20080287437A1 (en) 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
SI1888537T1 (sl) * 2005-05-26 2014-01-31 Janssen R&D Ireland Postopek priprave 4-((1,6-dihidro-6-okso-2-pirimidinil)amino benzonitrila
CN105348203B (zh) 2005-06-08 2018-09-18 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007044565A2 (en) * 2005-10-06 2007-04-19 University Of Massachusetts Composition and synthesis of new reagents for inhibition of hiv replication
WO2007049041A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
ES2327972T3 (es) 2006-01-19 2009-11-05 Janssen Pharmaceutica, N.V. Derivados de aminofenil como nuevos inhibidores de histona deacetilasa.
CN101370803B (zh) 2006-01-19 2012-12-12 詹森药业有限公司 作为组蛋白脱乙酰酶抑制剂的取代的吲哚基-烷基-氨基衍生物
DK1979326T3 (da) 2006-01-19 2013-01-07 Janssen Pharmaceutica Nv Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN101410394B (zh) 2006-03-30 2012-02-08 泰博特克药品有限公司 抑制人免疫缺陷病毒的5-(羟基亚甲基和氨基亚甲基)取代的嘧啶
KR20080114741A (ko) 2006-03-30 2008-12-31 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 5-아미도 치환 피리미딘
AR060890A1 (es) 2006-05-15 2008-07-23 Boehringer Ingelheim Int Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
CA2651665C (en) 2006-06-06 2010-04-27 Tibotec Pharmaceuticals Ltd. Process for preparing spray dried formulations of tmc125
WO2007149438A2 (en) 2006-06-19 2007-12-27 Alpharma, Inc. Pharmaceutical compositions
WO2008063301A2 (en) * 2006-10-11 2008-05-29 Alpharma, Inc. Pharmaceutical compositions
ES2624593T3 (es) 2006-12-06 2017-07-17 Janssen Sciences Ireland Uc Sal de hidrobromuro de un compuesto anti-VIH.
CN101573343B (zh) * 2006-12-29 2016-02-24 爱尔兰詹森科学公司 抑制人免疫缺陷病毒的6-取代的嘧啶
KR20090094084A (ko) 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 5,6-치환된 피리미딘
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
SI2300013T2 (sl) 2008-05-21 2025-05-30 Takeda Pharmaceutical Company Limited Fosforni derivati kot kinazni inhibitorji
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2727455C (en) 2008-06-27 2019-02-12 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
AR073760A1 (es) * 2008-10-03 2010-12-01 Astrazeneca Ab Derivados heterociclicos y metodos de uso de los mismos
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
CA2757228C (en) 2009-03-30 2018-01-02 Tibotec Pharmaceuticals Co-crystal of etravirine and nicotinamide
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
WO2010131118A2 (en) * 2009-05-12 2010-11-18 Pliva Hrvatska D.O.O. Polymorphs of etravirine and processes for preparation thereof
ES2527103T3 (es) 2009-06-22 2015-01-20 Emcure Pharmaceuticals Limited Procedimiento para la síntesis de etravirina
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
MA34299B1 (fr) 2010-06-04 2013-06-01 Hoffmann La Roche Dérivés d'aminopyrimidine au titre de modulateurs de lrrk2
EP2584901A4 (en) 2010-06-28 2013-10-09 Hetero Research Foundation PROCESS FOR PREPARING THE INTERMEDIATE OF STRAIN AND STRAIN OF POLYMORPHS
PT2603081T (pt) 2010-08-10 2017-01-13 Celgene Avilomics Res Inc Sal de besilato de um inibidor de btk
PE20131371A1 (es) 2010-09-22 2013-11-25 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
MX2013004894A (es) 2010-11-01 2013-10-17 Celgene Avilomics Res Inc Compuestos heterociclicos y usos de los mismos.
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
LT2638031T (lt) 2010-11-10 2017-12-11 Genentech, Inc. Pirazolo aminopiridino dariniai, kaip lrrk2 moduliatoriai
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
WO2012147104A1 (en) 2011-04-26 2012-11-01 Mylan Laboratories Ltd Novel process for the preparation of etravirine
BR112013027734A2 (pt) 2011-05-04 2017-08-08 Ariad Pharma Inc compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
ES2690971T3 (es) 2011-08-23 2018-11-23 Asana Biosciences, Llc Compuestos pirimido-piridazinona y uso de los mismos
WO2013059572A1 (en) 2011-10-19 2013-04-25 Assia Chemical Industries Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
WO2013138495A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
ES2698298T3 (es) 2012-03-15 2019-02-04 Celgene Car Llc Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
WO2014068588A2 (en) * 2012-10-29 2014-05-08 Biophore India Pharmaceuticals Pvt. Ltd. Process for the synthesis of etravirine and its intermediates
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
WO2014094176A1 (en) 2012-12-21 2014-06-26 Oncozyme Pharma Inc. Uses and methods for the treatment of liver diseases or conditions
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
KR102595163B1 (ko) 2015-01-06 2023-10-30 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 상태의 치료 방법
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
ES2929526T3 (es) 2015-06-22 2022-11-29 Arena Pharm Inc Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1
KR20190140011A (ko) 2017-04-28 2019-12-18 아사나 바이오사이언시스 엘엘씨 아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형
MA52778A (fr) 2018-06-06 2021-04-21 Arena Pharm Inc Méthodes de traitement de troubles associés au récepteur s1p1
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4659363A (en) * 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
ATE60591T1 (de) * 1984-06-25 1991-02-15 Ciba Geigy Ag Pyrimidinderivate wirksam als schaedlingsbekaempfungsmittel.
DD283613A5 (de) 1988-03-31 1990-10-17 ��@���������@�������k�� Verfahren zur herstellung von in 6-stellung substituierte acyclopyrimidin-nucleosid-derivaten
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
JP2895680B2 (ja) * 1992-07-08 1999-05-24 シャープ株式会社 磁気ヘッドおよびその製造方法
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
JP3398152B2 (ja) 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
NZ322907A (en) 1995-11-23 1998-12-23 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE29704863U1 (de) * 1997-03-17 1997-05-22 Gesellschaft für Innenhochdruckverfahren mbH & Co. KG, 73441 Bopfingen Achsschwinge
BR9908004A (pt) 1998-02-17 2001-12-18 Tularik Inc Composto, composição e método para prevençãoou supressão de uma infecção viral
DE69943247D1 (de) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
EP0945442A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
AP1468A (en) * 1998-03-27 2005-09-23 Janssen Pharmaceutica Nv Hiv inhibiting pyrimidine derivatives.
EE05086B1 (et) * 1998-11-10 2008-10-15 Janssen Pharmaceutica N.V. Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
CA2407754C (en) * 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines

Also Published As

Publication number Publication date
US20030114472A1 (en) 2003-06-19
DE69941934D1 (de) 2010-03-04
AU2011200708A1 (en) 2011-03-10
NO20011696L (no) 2001-04-04
HRP20080359B1 (hr) 2016-01-01
LTPA2008016I1 (lt) 2021-04-26
CY2008021I2 (el) 2010-07-28
MY121108A (en) 2005-12-30
EP1002795A1 (en) 2000-05-24
HRP20010161B9 (hr) 2014-10-24
IL169949A (en) 2011-02-28
HK1048817A1 (en) 2003-04-17
US7037917B2 (en) 2006-05-02
EE05086B1 (et) 2008-10-15
AP1683A (en) 2006-11-29
KR100658489B1 (ko) 2006-12-18
HRP20080359A2 (en) 2008-12-31
US20050288278A1 (en) 2005-12-29
NZ511116A (en) 2003-08-29
DE69905683T2 (de) 2004-03-18
AU762523B2 (en) 2003-06-26
BR9915552A (pt) 2001-08-14
HUP0104177A2 (hu) 2002-03-28
PL204427B1 (pl) 2010-01-29
CZ20011533A3 (cs) 2001-10-17
TR200101306T2 (tr) 2001-10-22
HU227453B1 (en) 2011-06-28
LU91528I2 (fr) 2009-04-20
ES2338760T3 (es) 2010-05-12
NL300373I2 (nl) 2009-04-01
EA004049B1 (ru) 2003-12-25
WO2000027825A1 (en) 2000-05-18
NO2021015I1 (no) 2021-03-29
IL143023A0 (en) 2002-04-21
US8003789B2 (en) 2011-08-23
SK287270B6 (sk) 2010-05-07
CN1322198A (zh) 2001-11-14
SK6032001A3 (en) 2002-01-07
KR20010075235A (ko) 2001-08-09
PL347586A1 (en) 2002-04-08
BR9915552B1 (pt) 2013-11-19
HRP20010161B1 (en) 2009-03-31
ES2193664T3 (es) 2003-11-01
AR024227A1 (es) 2002-09-25
HK1048817B (en) 2010-04-09
NO2009003I1 (no) 2009-03-09
US6878717B2 (en) 2005-04-12
NL300373I1 (nl) 2009-03-02
US20040039005A1 (en) 2004-02-26
TWI238161B (en) 2005-08-21
OA11674A (en) 2005-01-12
BRPI9915552B8 (pt) 2021-05-25
US20080176880A1 (en) 2008-07-24
EP1270560A1 (en) 2003-01-02
EE200100252A (et) 2002-10-15
JP2002529456A (ja) 2002-09-10
DE69905683D1 (de) 2003-04-10
DK1002795T3 (da) 2003-06-30
ID28376A (id) 2001-05-17
ATE455107T1 (de) 2010-01-15
CZ301367B6 (cs) 2010-02-03
HUP0104177A3 (en) 2003-01-28
SK287269B6 (sk) 2010-05-07
UA70966C2 (uk) 2004-11-15
US20110263625A1 (en) 2011-10-27
US8530655B2 (en) 2013-09-10
BG105418A (en) 2001-11-30
EP1002795B1 (en) 2003-03-05
LTC1002795I2 (lt) 2021-06-10
HU230394B1 (hu) 2016-04-28
BG65103B1 (bg) 2007-02-28
HK1025330A1 (en) 2000-11-10
NO318801B1 (no) 2005-05-09
DE122009000003I1 (de) 2009-05-20
HRP20010161A2 (en) 2002-02-28
EP1270560B1 (en) 2010-01-13
FR09C0004I2 (fr) 2010-06-11
CA2350801C (en) 2008-05-20
EA200100536A1 (ru) 2002-02-28
ATE233740T1 (de) 2003-03-15
CA2350801A1 (en) 2000-05-18
AU762523C (en) 2004-02-12
CY2008021I1 (el) 2010-07-28
LU91528I9 (enrdf_load_stackoverflow) 2019-01-02
SI1002795T1 (en) 2003-10-31
JP3635238B2 (ja) 2005-04-06
NO20011696D0 (no) 2001-04-04
ZA200103769B (en) 2002-08-12
AU6200899A (en) 2000-05-29
PT1002795E (pt) 2003-07-31
NO2009003I2 (no) 2010-06-07
CN1214013C (zh) 2005-08-10

Similar Documents

Publication Publication Date Title
BE2014C048I2 (enrdf_load_stackoverflow)
JP2003529228A5 (enrdf_load_stackoverflow)
BRPI9917862A2 (enrdf_load_stackoverflow)
BRPI9914151B8 (enrdf_load_stackoverflow)
JP2003518954A5 (enrdf_load_stackoverflow)
JP2002510510A5 (enrdf_load_stackoverflow)
BRPI9816295A2 (enrdf_load_stackoverflow)
BRPI9917863A2 (enrdf_load_stackoverflow)
CN3078569S (enrdf_load_stackoverflow)
CN3079461S (enrdf_load_stackoverflow)
CN3072760S (enrdf_load_stackoverflow)
CN3072761S (enrdf_load_stackoverflow)
CN3073190S (enrdf_load_stackoverflow)
CN3073425S (enrdf_load_stackoverflow)
CN3073771S (enrdf_load_stackoverflow)
CN3073964S (enrdf_load_stackoverflow)
CN3074052S (enrdf_load_stackoverflow)
CN3074054S (enrdf_load_stackoverflow)
CN3074547S (enrdf_load_stackoverflow)
CN3074964S (enrdf_load_stackoverflow)
CN3075591S (enrdf_load_stackoverflow)
CN3075658S (enrdf_load_stackoverflow)
CN3076421S (enrdf_load_stackoverflow)
BY6371C1 (enrdf_load_stackoverflow)
CN3078962S (enrdf_load_stackoverflow)